CharlesR: First of all, let me say that I have sufficient funding for whole body, yet I have chosen the neuro option. I find it difficult to fathom why anyone would want to bring along a broken-down old body which is going to have to be replaced anyway. We can store ten neuro patients for the cost of one whole body patient (which means that we are probably underpricing WBs currently). A neuro arrangement with Alcor currently costs $80,000. Although WB prices may have to rise before long, I’ve heard no suggestion that neuro rates need to rise anytime soon.
However, assuming someone is determined to take along their complete body, no matter how old and infirm, to answer your question: You CURRENTLY need a MINIMUM of $200,000. At that rate, we are currently drawing between 3% and 4% of the amount going into the Patient Care Trust for indefinite care and eventual revival. That may be sustainable, but is more than our desired conservative estimates. We aim to draw no more than 2% per year. Currently, I’m driving to reduce our costs, especially for liquid nitrogen. Early next year, we should be able to revise our contract and bring these down significantly.
Even so, you should plan to have available not $200,000, but that amount compounded by something like the general rate of inflation. (Your cost doubling rate of 20 years looks close to me. I think it’s maybe 22 or 23 years, given a century-long average, but very close...) Unfortunately, some cryonicists have assumed that costs would remain unchanged. Given the history of inflation, that expectation is simply either ignorant or irrational. I would urge every cryonicist to plan for costs to rise by at least the historical long-run average of about 3% annually.
How do you plan for that? You might take out considerably more life insurance initially. You might take out the current minimum or a bit more, then over time supplement that by prepaying additional amounts. We are currently figuring out various options that might help deal with the annoying but inevitable reality of inflation.
If you, or anyone else, would like to discuss this in more detail and in a more personal way, please, please, please, call me at 480.905.1906 x113
--Max
“However, Alcor remains something of a shadowy organization that many within the cryonics community are suspicious of.”
Really? That’s a remarkable statement. Alcor has a long history of open communication with its members and the cryonics community in general. Among the ways Alcor does this:
Cryonics magazine
Alcor News emailings
RSS feed
conferences
case reports
extremely detailed website with information on finances, governance… everything
Facebook page
Member Forums
See: http://www.alcor.org/newatalcor.html
“Mike Darwin, a former Alcor president, has written at length on both organizations at http://www.chronopause.com, and on the whole, at least based on what I’ve read, Alcor comes across looking less competent, less trustworthy, and less open than CI.”
Darwin is a member of Alcor, not CI. How do you explain that? Darwin thoroughly enjoys criticizing Alcor (rightly or not) but remains a member. In a related comment, ahartnell says “from what I have read both seem to provide basically the same service”.
This is a remarkable belief. Alcor uses the most advanced cryoprotectant, M22, to perfuse whole bodies and neuros. CI uses a less advanced (and cheaper) cryoprotectant but cryoprotects ONLY THE HEAD, allowing the rest of the body to be straight frozen with massive damage. That’s especially odd since (many of) CI members are insistent about being whole body patients rather than neuros.
Also, and VERY importantly, ischemic time matters hugely. CI members can get standby and transport services from SA by paying a fee (one that makes Alcor neuros significantly LESS expensive). Otherwise, except for CI members undergoing clinical death in the Detroit area, this means long ischemic times and tremendous damage. When I was at CI’s 2011 AGM, Aschwin and Chana de Wolf presented their research findings showing the frightening damage done by extended ischemic time. They also showed that a large majority of CI patients experienced that damage. Staggeringly, no one objected, challenged them, or seem the least concerned.
You mention Mike Darwin, yet note that in Figure 11 of a recent analysis by him, he says that 48 percent of patients in Alcor’s present population experienced “minimal ischemia.” Of CI, Mike writes, “While this number is discouraging, it is spectacular when compared to the Cryonics Institute, where it is somewhere in the low single digits.”
As to Ralph Merkle’s comments: His frank assessment of past practices contradicts the claim that Alcor is secretive. His comments were also about past practices. Unlike CI, Alcor has created robust practices and mechanisms for long-term maintenance and growth of the Patient Care Trust Fund and the Endowment Fund. Go take a look at CI’s financial reports. See how little money is available for the indefinite care and eventual revival of each patient. Also look at the returns on investment of those funds.
For those interested in comparing Alcor and CI, plenty of basic factual information is available here:
http://www.alcor.org/FAQs/faq06.html#choose